Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 2/2010

01.03.2010

Topical Antibiotic Therapy of Chronic Rhinosinusitis

verfasst von: Richard H. Comstock III, Kent Lam, Suzette Mikula

Erschienen in: Current Infectious Disease Reports | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Many different treatment options for chronic rhinosinusitis (CRS) exist, but questions remain regarding the best options. Although oral and intravenous antimicrobial therapies have traditionally been prescribed to manage CRS, topical administration of these agents has gained increasing popularity over the past few years. Topical antimicrobial agents are preferable because of their ability to localize delivery to the sinonasal mucosa and minimize the systemic effects seen with oral agents. This quality is especially important in treatment of biofilms, where higher concentrations of antibiotics are usually required. This article gives a brief overview of CRS and provides a summary of recent studies using topical agents for treatment of bacterial and fungal sinusitis.
Literatur
1.
Bhattacharyya N: The economic burden and symptom manifestations of chronic rhinosinusitis. Am J Rhinol 2003, 17:27–32.PubMed
2.
Wasan A, Fernandez E, Jamison RN, et al.: Association of anxiety and depression with reported disease severity in patients undergoing evaluation for chronic rhinosinusitis. Ann Otol Rhinol Laryngol 2007, 116:491–497.PubMed
3.
•• Rosenfeld RM, Andes D, Bhattacharyya N, et al.: Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007, 137:S1–S31. This article, written by a panel selected by the American Academy of Otolaryngology-Head and Neck Surgery, provides a comprehensive guideline with recent evidence-based recommendations on the diagnosis and management of acute and chronic forms of rhinosinusitis in adult populations.CrossRefPubMed
4.
Benninger MS, Ferguson BJ, Hadley JA, et al.: Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology and pathophysiology. Otolaryngol Head Neck Surg 2003, 129(3 Suppl):S1–S32.CrossRefPubMed
5.
Chan Y, Kuhn FA: An update on the classifications, diagnosis, and treatment of rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2009, 17:204–208.CrossRefPubMed
6.
Sharp HJ, Denman D, Puumala S, et al.: Treatment of acute and chronic rhinosinusitis in the United States, 1999–2002. Arch Otolaryngol Head Neck Surg 2007, 133:260–265.CrossRefPubMed
7.
Burton MJ, Eisenberg LD, Rosenfeld RM: Extracts from The Cochrane Library: nasal saline irrigations for the symptoms of chronic rhinosinusitis. Otolaryngol Head Neck Surg 2007, 137:532–534.CrossRefPubMed
8.
Aukuma A, Mulder P, Fokkens W: Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. J Allergy Clin Immunol 2005, 115:1017–1023.CrossRef
9.
Osguthorpe JD: Surgical outcomes in rhinosinusitis: what we know. Otolaryngol Head Neck Surg 1999, 120:451–453.CrossRefPubMed
10.
Bhattacharyya N: Clinical outcomes after endoscopic sinus surgery. Curr Opin Allergy Clin Immunol 2006, 6:167–171.CrossRefPubMed
11.
• Hilton C, Wiedmann T, St. Martin M, et al.: Differential deposition of aerosols in the maxillary sinus of human cadavers by particle size. Am J Rhinol 2008, 22:395–398. This research analyzed the delivery of nebulized particles in the paranasal sinuses of four human cadavers, and found that particle size and nasal anatomy were both contributing factors that affected the deposition of particles into the maxillary sinus.CrossRefPubMed
12.
Goh YH, Goode RL: Current status of topical nasal antimicrobial agents. Laryngoscope 2000, 110:875–880.CrossRefPubMed
13.
Mahoney EJ, Metson R: Palliative care for the patient with refractory chronic rhinosinusitis. Otolaryngol Clin North Am 2009, 42:39–47, vii–viii.CrossRefPubMed
14.
Davis LJB, Kita H: Pathogenesis of chronic rhinosinusitis: role of airborne fungi and bacteria. Immunol Allergy Clin North Am 2004, 24:59–73.CrossRefPubMed
15.
Brook I: The role of bacteria in chronic rhinosinusitis. Otolaryngol Clin North Am 2005, 38:1171–1192.CrossRefPubMed
16.
Sanclement JA, Webster P, Thomas J, Ramadan HH: Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis. Laryngoscope 2005, 115:578–582.PubMed
17.
Sanderson AR, Leid JG, Hunsaker D: Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 2006, 116:1121–1126.CrossRefPubMed
18.
• Post JC, Hiller NL, Nistico L et al.: The role of biofilms in otolaryngologic infections: update 2007. Curr Opin Otolaryngol Head Neck Surg 2007, 15:347–351. This review article highlights current understanding of bacterial biofilm and its impact in the pathogenesis of different head and neck infections.CrossRefPubMed
19.
Ramadan HH, Sanclement JA, Thomas JG: Chronic rhinosinusitis and biofilms. Otolaryngol Head Neck Surgery 2005, 132:414–417.CrossRef
20.
Seiberling KA, Grammer L, Kern RC: Chronic rhinosinusitis and superantigens. Otolaryngol Clin North Am 2005, 38:1215–1236.CrossRefPubMed
21.
Ferguson BJ: Categorization of eosinophilic chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2004, 12:237–242.CrossRefPubMed
22.
Gosepath J, Mann WJ: Role of fungus in eosinophilic sinusitis. Curr Opin Otolaryngol Head Neck Surg 2005, 13:9–13.CrossRefPubMed
23.
Ponikau JU, Sherris DA, Kern EB, et al.: The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999, 74:877–884.CrossRefPubMed
24.
Dinis PB, Monteiro MC, Lobato R, et al.: Penetration of cefuroxime into chronically inflamed sinus mucosa. Laryngoscope 1999, 109:1841–1847.CrossRefPubMed
25.
Dinis PB, Monteiro MC, Martins ML, et al.: Soft tissue pharmacokinetics after oral administration of amoxicillin/clavulanic acid. Laryngoscope 2000, 110:1050–1055.CrossRefPubMed
26.
Hardy JG, Lee SW, Wilson CG: Intranasal drug delivery by spray and drops. J Pharm Pharmacol 1985, 37:294–297.PubMed
27.
Aoki FY, Crawley JCW: Distribution and removal of human albumin-technetium 99 m instilled intransally. J Pharm Pharmacol 1976, 3:869–878.
28.
Lim M, Citardi MJ, Leong JL: Topical antimicrobials in the management of chronic rhinosinusitis: A systematic review. Am J Rhinol 2008, 22:381–389.CrossRefPubMed
29.
Suman JD, Laube BL, Dalby R: Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. J Aerosol Med 2006, 19:510–521.CrossRefPubMed
30.
•• Uren B, Psaltis A, Wormald PJ: Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. Laryngoscope 2008, 118:1677–1680. This study determined that mupirocin appears to be an effective means of treatment for postsurgical patients with S. aureus-positive exacerbations of their disease.CrossRefPubMed
31.
32.
Ponikau JU, Sherris DA, Kita H: Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol 2002, 110:862–866.CrossRefPubMed
33.
Weschta M, Rimek D, Formanek M, et al.: Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol 2004, 113:1122–1128.CrossRefPubMed
34.
Helbling A, Baumann A, Hanni C, Caversaccio M: Amphotericin B nasal spray has no effects on nasal polyps. J Laryngol Otol 2006, 120:1023–1025.CrossRefPubMed
35.
Ponikau JU, Sherris DA, Weaver A, Kita H: Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol 2005, 115:125–131.CrossRefPubMed
36.
•• Ebbens FA, Scadding GK, Badia L, et al.: Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 2006, 118:1149–1156. This prospective, placebo-controlled, double-blind study showed no statistical difference between amphotericin and placebo in both subjective and objective measures.CrossRefPubMed
37.
Shirazi MA, Stankiewicz JA, Kammeyer P: Activity of nasal amphotericin B irrigation against fungal organisms in vitro. Am J Rhinol 2007, 21:145–148.CrossRefPubMed
38.
Desrosiers M, Bendouah Z, Barbeau J: Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro. Am J Rhinol 2007, 21:149–153.CrossRefPubMed
39.
•• Ha KR, Psaltis AJ, Butcher AR, et al.: In vitro activity of mupirocin on clinical isolated of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope 2008, 118:535–540. In this in vitro study comparing the efficacy of mupirocin, ciprofloxacin, and vancomycin on S. aureus biofilms, the authors determined that mupirocin was the only suitable choice for intranasal delivery because of its efficacy and lack of potential side effects.CrossRefPubMed
40.
Nadel DM, Lanza DC, Kennedy DW: Endoscopically guided sinus cultures in normal subjects. Am J Rhinol 1999, 13:87–90.CrossRefPubMed
41.
Ceri H, Olson ME, Stremick C, et al.: The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37:1771–1776.PubMed
42.
• Chiu AG, Antunes MB, Plamer JN, et al.: Evaluation of the in vivo efficacy of topical tobramycin against Pseudomonas sinonasal biofilms. J Antimicro Chemo 2007, 59:1130–1134. This in vivo study performed in a rabbit model found that topical tobramycin was ineffective in eradicating Pseudomonas biofilms.CrossRef
43.
Scheinberg PA, Otsuji A: Nebulized antibiotics for the treatment of acute exacerbations of chronic rhinosinusitis. Ear Nose Throat J 2002, 81:648–652.PubMed
44.
Vaughan WC, Carvalho G: Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol Head Neck Surg 2002, 127:558–568.CrossRefPubMed
45.
• Desrosiers MY, Salas-Prato M: Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial. Otol Head Neck Surg 2001, 125:265–269. This study found no statistical difference between saline irrigation and tobramycin irrigation in regards to quality of life, symptoms, and endoscopy findings.CrossRef
Metadaten
Titel
Topical Antibiotic Therapy of Chronic Rhinosinusitis
verfasst von
Richard H. Comstock III
Kent Lam
Suzette Mikula
Publikationsdatum
01.03.2010
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 2/2010
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0085-4

Weitere Artikel der Ausgabe 2/2010

Current Infectious Disease Reports 2/2010 Zur Ausgabe

ReviewPaper

Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men

ReviewPaper

Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men

ReviewPaper

Evaluation and Management of Syphilis in the HIV-Infected Patient

Clinical Trial Report

The Next Era of HCV Antiviral Therapy Finally Begins: Part 1

ReviewPaper

The Role of Adenovirus in Respiratory Tract Infections

ReviewPaper

β-Lactamase–Producing Bacteria in Upper Respiratory Tract Infections

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise